Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trialOriginal Article Published on 2018-05-272024-09-02 Journal: Annals of Hematology [Category] 대상포진, [키워드] Chronic myeloproliferative disorders JAK inhibitor polycythemia vera ruxolitinib [DOI] 10.1007/s00277-018-3365-y PMC 바로가기 [Article Type] Original Article